CRITICAL UPDATE — ALL ByHeart Formulas Are Pulled

Person holding megaphone, Product Recall text.

A formula company that marketed itself as the safest alternative to legacy brands now faces allegations linking its products to 51 infant botulism cases across 19 states, exposing dangerous regulatory gaps that put America’s most vulnerable at risk.

Story Highlights

51 infants across 19 states developed botulism or botulism-like illness potentially linked to ByHeart powdered formula
ByHeart built its brand on “superior safety” and owned manufacturing after the Abbott formula crisis
Federal investigations continue while affected families file civil lawsuits seeking accountability
The cluster represents an unusually large outbreak for rare infant botulism cases

Marketing Claims Versus Reality

ByHeart founders Mia Funt and Ron Belldegrun launched their company in 2016 with promises to “transform baby nutrition” through superior safety controls. The siblings spent years developing what they marketed as a cleaner, safer alternative to established formula brands, emphasizing their ownership of a Reading, Pennsylvania manufacturing facility as a key differentiator from contract manufacturers.

The company positioned itself as “only the fourth fully integrated, FDA-registered infant nutrition brand in the US” and conducted what it claimed was “the largest US clinical trial for a new infant formula brand in 25 years.” ByHeart’s marketing heavily emphasized Clean Label Project certification and breast milk-inspired formulation to attract parents seeking premium alternatives.

Dangerous Pattern Emerges

Starting in late 2022, sporadic infant illnesses began appearing in state health records, with affected babies showing neuromuscular weakness, poor feeding, constipation, and hypotonia consistent with botulism presentations. Some cases required respiratory support as the potentially life-threatening condition progressed through vulnerable infants’ systems.

As cases accumulated across multiple states, epidemiologists discovered a troubling common factor: ByHeart formula repeatedly appeared in dietary histories of affected infants. State health departments began notifying the CDC and FDA as the pattern became impossible to ignore, leading to federal investigations into possible Clostridium botulinum contamination.

Federal Response Falls Short

Despite the serious nature of these allegations, no final federal report has conclusively determined causality between ByHeart formula and the 51 infant cases. This regulatory gap mirrors the failures that allowed the Abbott Sturgis plant crisis to develop, where Cronobacter contamination led to hospitalizations, deaths, and nationwide formula shortages.

51 babies across 19 states fall ill from botulism linked to ByHeart baby formula https://t.co/6R4U36tlfC

— FOX Business (@FoxBusiness) December 12, 2025

The FDA’s post-Abbott reforms focused primarily on Cronobacter and Salmonella risks while apparently missing surveillance gaps for other dangerous pathogens like C. botulinum. This oversight is particularly concerning given that infant botulism cases are historically rare, making a 19-state cluster statistically significant and demanding immediate decisive action from federal regulators.